Periodic Reporting for period 1 - eLive.care (The New Era of Self-Care's Digitalisation. Better Health with Lower Costs More Individually.)
Okres sprawozdawczy: 2019-01-01 do 2019-05-31
The global population is projected to reach 10 billion people by 2050. Chronic diseases are rising: 73% of all deaths are expected to result from chronic diseases by 2020. Populations are aging: the number of people aged 60 years and older will rise from 900 million to 2 billion between 2015 and 2050; that’s a rise from 12% to 22% of the total global population. Treatment of chronic diseases create 80% of healthcare costs in the EU, annually €115 billion. The amount is continuously rising as the population ages and chronic diseases affect 8 out of 10 people aged 65 and older. However, 50-80% of chronic diseases can be prevented by reducing the risk factors and ensuring good living environment.
In this new era of digital connection, patients are transitioning from passive healthcare recipients to active value-seeking consumers. Healthcare must answer this change. eLive Ecosystem Oy offers an answer: one of a kind holistic solution for preventive and self-acting healthcare. The artificial intelligence, sensor technology and genetic testing -based health ecosystem offers new possibilities to independently and individually prevent most common chronic diseases, such as cardiovascular diseases, type 2 diabetes and sleep apnea and their disadvantages.
The breakthrough innovative eLive.care -solution combines genomic tests and several at home measurements of health (ambulatory blood pressure monitor, blood glucose, cholesterol levels, sleep cycles, blood oxygen saturation) and environment (interior air quality monitors). With the support of Artificial Intelligence, the solution guides the user to independently, medically effectively and based on individual risk-factors prevent chronic diseases and their disadvantages. With the support of eLive.care -innovation several significant chronic diseases (such as sleep apnea, cardiovascular diseases and type 2 diabetes) can be detected prior to experiencing any symptom and therefore prevented.
The impacts of at-home preventive care are huge, the aim is to prevent over 10,000 chronicity of the disease in five years and create €100M saving in healthcare costs. The solution is currently under piloting and will be launched to the market with in-house and partner sales in 2020.
The Finnish start-up, eLive Ecosystem Oy, has enthusiastic team of nine with core competence in medical, technical and business development as well as strong partner network to support the commercialisation and scale-up.
The aim of this feasibility study was to analyse the feasibility from different perspectives.
In this new era of digital connection, patients are transitioning from passive healthcare recipients to active value-seeking consumers. Healthcare must answer this change. eLive Ecosystem Oy offers an answer: one of a kind holistic solution for preventive and self-acting healthcare. The artificial intelligence, sensor technology and genetic testing -based health ecosystem offers new possibilities to independently and individually prevent most common chronic diseases, such as cardiovascular diseases, type 2 diabetes and sleep apnea and their disadvantages.
The breakthrough innovative eLive.care -solution combines genomic tests and several at home measurements of health (ambulatory blood pressure monitor, blood glucose, cholesterol levels, sleep cycles, blood oxygen saturation) and environment (interior air quality monitors). With the support of Artificial Intelligence, the solution guides the user to independently, medically effectively and based on individual risk-factors prevent chronic diseases and their disadvantages. With the support of eLive.care -innovation several significant chronic diseases (such as sleep apnea, cardiovascular diseases and type 2 diabetes) can be detected prior to experiencing any symptom and therefore prevented.
The impacts of at-home preventive care are huge, the aim is to prevent over 10,000 chronicity of the disease in five years and create €100M saving in healthcare costs. The solution is currently under piloting and will be launched to the market with in-house and partner sales in 2020.
The Finnish start-up, eLive Ecosystem Oy, has enthusiastic team of nine with core competence in medical, technical and business development as well as strong partner network to support the commercialisation and scale-up.
The aim of this feasibility study was to analyse the feasibility from different perspectives.
The feasibility study covered technical, market and financial feasibility. The results were gathered to a full business plan for the global commercialisation of the eLive.care -solution. The first commercial product will be launched in early 2020 for sleep apnea. The scale-up to several other diseases (five modules in total) will follow quickly.
The scale-up strategy has been estimated and developed during the project. New partnerships have been formed to support the technology finalisation, validation and business scale-up. The company has confirmed the feasibility of the technology and detailed the stages towards global commercialisation.
The scale-up strategy has been estimated and developed during the project. New partnerships have been formed to support the technology finalisation, validation and business scale-up. The company has confirmed the feasibility of the technology and detailed the stages towards global commercialisation.
The project resulted in a full business plan describing the steps to market. The impacts of the overall commercialisation project by 2025 includes +80,000 eLive.care -devices sold and +€190M yearly revenue, and 200 direct and +1000 indirect workplaces.